Russo Rene
SEC CIK 1722066 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| XLO | Xilio Therapeutics, Inc. | Pres AND CEO, Dir | 325.4K | $24.7K | — | 3 | 2025-01-01 | 2026-01-01 |
Most active insiders at XLO, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Shannon James Samuel | Dir | $43.9K | — |
| 2 | Frankenfield Christopher James | CFO | — | $4,499 |
| 3 | Brennan Kevin M. | SVP, Fin AND ACCOUNTING | — | $1,169 |
| 4 | Luptakova Katarina | Chief MEDICAL Off | — | — |
| 5 | Russo Rene | Pres AND CEO, Dir | — | — |
Transactions 3
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-01-05 | 2026-01-01 | XLO | Xilio Therapeutics, Inc. | Russo Rene | Pres AND CEO, Dir | M - OptEx | — | +44.2K | 325.4K | +16% | — |
| 2025-06-18 | 2025-06-16 | XLO | Xilio Therapeutics, Inc. | Russo Rene | Pres AND CEO, Dir | P - Purchase | $0.68 | +36.3K | 281.2K | +15% | +$24.7K | |
| D | 2025-01-03 | 2025-01-01 | XLO | Xilio Therapeutics, Inc. | Russo Rene | Pres AND CEO, Dir | M - OptEx | — | +44.2K | 244.9K | +22% | — |
Purchase Sale Sale after option exercise All abbreviations